ALCMI’s Genomics of Young Lung Cancer Study (GoYLC) was chosen as one of 30 of the most creative, cross-sector collaborations in medical research from a field of 120 applicants to present its model to potential partners and funders at FasterCures’ sixth annual Partnering for Cures conference this past November in New York City.
Selected through a competitive proposal process, these partnerships are aimed at reducing the time and cost of getting new medical solutions from discovery to patients and speeding the path to cures, and they feature innovative approaches to increase patient access to clinical studies.
Our Genomics of Young Lung Cancer study is a truly first-of-its-kind international, prospective study looking beyond the genomic alterations most commonly associated with lung cancer and identifying the novel and unique alterations that present in cancers in adolescents and young adults. This study will help us understand why and how the disease occurs in young adults and non-smokers, and crucially, to enable the development of new targeted therapies for this under-served population. We would now like to highlight an early accomplishment.
The study’s planned enrollment goal was 60 genomically-tested patients over two years due to the challenge of identifying, recruiting and enabling participation of a geographically dispersed, relatively rare patient population. Rather incredibly, we were able to enroll 50% of the planned enrollment goal — 30 out of the 60 patients — in the first three weeks of the study, with virtually all of the initial patients participating remotely in the U.S., U.K. and Europe. The extraordinarily rapid accrual to this initiative was “super-charged” by the combined efforts of ALCMI (clinical study development and operations infrastructure), ALCF (existing patient database and de novo outreach via social media, traditional media such as television and print news stories), Foundation Medicine (class-leading clinical genomics panels), and Open Medicine Institute (remote consenting and electronic data capture technologies).
As a result of our cutting-edge approach to remote patient screening, consenting and participation, ALCMI was awarded a highly competitive Innovator Presentation slot at the Partnering for Cures conference. View/hear the recorded presentation here
Patient-centric advocacy and research organizations such as ALCMI and ALCF have created new models of directed research and are DRIVING advanced new and more effective diagnostics and therapeutics that improve patient outcomes. These new models of research go where the patients are and open up new channels of access for enrollment, making research and the benefits of participation more accessible to a patient group who has historically been least represented in clinical trials.
As a direct result of accelerated enrollment to the genomics study, ALCMI researchers have already begun developing the follow-on studies, including an international epidemiology study, expanded genomics, investigating potential causes of lung cancer in never-smoking populations (environmental exposures, viruses, and more) and, critically, having opened discussions with the bio-pharmaceutical industry to develop or apply targeted therapies for the affected lung cancer populations in the U.S. and globally.
CALL TO ACTION: Do you know a young person who might benefit from enrollment in ALCMI’s Genomics of Young Lung Study? If so, please contact [email protected].